Selected EMA news, 2025

December 2025

New information on approved medicines 

  • Aspaveli (pegcetacoplan) – new indication – orphan 
    Treatment of paroxysmal nocturnal hemoglobinuria (PNH), an acquired disease in which there is excessive breakdown of red blood cells, leading to large amounts of hemoglobin being released into the urine 

Direct Healthcare Professional Communication (DHPC) 

November 2025

New medicines recommended for approval

  • Waskyra (autologous CD34+ hematopoietic stem cells transduced ex vivo with a lentiviral vector encoding human Wiskott-Aldrich syndrome protein)  
    Treatment of Wiskott-Aldrich syndrome (an inherited disease affecting blood cells and cells of the immune system, the body’s natural defenses) 

New information on approved medicines 

  • Minjuvi (tafasitamab) – new indication 
    Treatment of large B-cell lymphoma (cancer of white blood cells) 
  • Veyvondi (vonicog alfa) – extension of indication 
    Prevention and treatment of bleeding in patients with Willebrand disease (an inherited bleeding disorder) 

Direct Healthcare Professional Communication (DHPC) 

  • Lenalidomide Mylan (lenalidomide) 
    Treatment of multiple myeloma (cancer of the bone marrow) 

Supply shortage 

  • Beriglobin
    Replacement therapy for adults and children who lack immunoglobulins and are at risk of infection. This includes people with chronic lymphocytic leukemia or multiple myeloma who have hypogammaglobulinemia and recurrent bacterial infections, as well as people who are undergoing or have undergone an allogeneic hematopoietic stem cell transplant and have hypogammaglobulinemia.

October 2025

New medicines approved

  • Vivlipeg (pegfilgrastim) 
    Treatment during cancer to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment 

New medicines recommended for approval

  • Wayrilz (rilzabrutinib)  
    Treatment of immune thrombocytopenia (when the body’s immune system destroys healthy platelets in the blood. Platelets are needed to form clots and stop bleeding) 

New information on approved medicines 

  • Breyanzi (lisocabtagene maraleucel) – new indication 
    Treatment of different types of lymphoma (cancer of white blood cells) 
  • Gazyvaro (obinutuzumab) – new indication – orphan 
    Treatment of chronic lymphocytic leukemia,  follicular lymphoma (both are cancers of B-lymphocytes, a type of white blood cell) 
  • Pyrukynd (mitapivat) – new indication – orphan 
    Treatment of pyruvate kinase deficiency (an inherited disease that causes red blood cells to break down faster than normal) and anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia
  • Scemblix (asciminib) – change of indication – orphan 
    Treatment of chronic myeloid leukemia (a cancer of the white blood cells) 

Other EMA news

  • EMA has confirmed suspension of the sickle cell disease medicine Oxbryta.
    EMA’s human medicines committee (CHMP) has recommended that the marketing authorization of Oxbryta remain suspended. This recommendation follows interim measures taken by the Committee in September 2024, when it temporarily suspended the medicine to review emerging safety data.

September 2025

New information on approved medicines 

  • Lunsumio (mosunetuzumab) – new route of administration / new pharmaceutical form / new strengths
    Treatment of follicular lymphoma (a type of blood cancer) 
  • Keytruda (pembrolizumab) – new pharmaceutical form
    Treatment of several types of cancer, including Classical Hodgkin lymphoma 

Withdrawal of applications for new medicines 

  • Fanskya (mozafancogene autotemcel)
    Treatment of fanconi anemia type A, an inherited condition that affects the bone marrow, the spongy tissue inside the large bones where blood cells are made 

August 2025

New information on approved medicines

  • Alhemo (concizumab) – extension of indication
    Treatment of hemophilia A and B

Withdrawal of applications for new medicines

  • Aplidin (plitidepsin)
    Intended for the treatment of multiple myeloma (cancer of the bone marrow)

July 2025

New medicines recommended for approval

  • Imreplys (sargramostim)
    Treatment of hematopoietic acute radiation syndrome (depletion of blood cells caused by exposure to radiation)
  • Vivlipeg (pegfilgrastim) – biosimilar
    Chemotherapy-induced neutropenia (low level of white blood cells)
  • Zemcelpro (allogeneic umbilical cord-derived CD34- cells, non-expanded / dorocubicel) – orphan
    Treatment of hematological malignancies (blood cell cancers) requiring stem cell transplantation

New information on approved medicines

  • Darzalex (daratumumab) – new indication
    Treatment of multiple myeloma (a cancer of the bone marrow)
  • Imbruvica (ibrutinib) – new indication
    Treatment of mantle cell lymphoma (blood cancers) in patients who are eligible for stem cell transplantation
  • Sarclisa (isatuximab) – new indication
    Treatment of multiple myeloma (a cancer of the bone marrow)

June 2025

New medicines recommended for approval

  • Aucatzyl (obecabtagene autoleucel) – orphan medicine – conditional approval
    Treatment of lymphoblastic leukaemia (blood cancer)
  • Blenrep (belantamab mafodotin)
    Treatment of multiple myeloma (blood cancer)

Supply shortages

  • NovoSeven (eptacog alfa) (eptacog alfa (activated))
    Treatment of bleeding episodes and prevention of bleeding after surgical procedures

May 2025

New information on approved medicines

  • Adcetris (brentuximab vedotin) – new indication
    Treatment of lymphomas (cancers of lymphocytes, white blood cells that are part of the immune system)
  • Calquence (acalabrutinib) – new indication
    Treatment of chronic lymphocytic leukemia, a blood cancer affecting B cells (a type of white blood cell)
  • Jivi (damoctocog alfa pegol) – extension of indication
    Treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder)

Supply shortages

  • NovoSeven (eptacog alfa (activated))
    Treatment of bleeding episodes and prevention of bleeding after surgical procedures

April 2025

New medicines recommended for approval

  • Xoanacyl (ferric citrate coordination complex)
    Treatment of concomitant hyperphosphatemia and iron deficiency in adults with chronic kidney disease

New information on approved medicines

  • Bosulif (bosutinib) – extension of indication and new pharmaceutical form
    Treatment of myeloid leukemia (blood cancer)
  • Calquence (acalabrutinib) – new indication
    Treatment of lymphoma and leukemia (blood cancers)

Negative CHMP opinions on extension of indication

  • Pemazyre (pemigatinib)
    Intended to treat myeloid/lymphoid neoplasms (blood cancers)

March 2025

New medicines recommended for approval

  • Lynozyfic (linvoseltamab)
    Treatment of refractory multiple myeloma (a cancer of the bone marrow)

New information on approved medicines

  • Calquence (acalabrutinib) – new indication
    Treatment of blood cancer
  • Columvi (glofitamab) – new indication
    Treatment of blood cancer
  • Darzalex (daratumumab) – change of indication
    Treatment of multiple myeloma (a cancer of the bone marrow) and light chain amyloidosis (a blood disease in which deposits of abnormal proteins, called amyloids, accumulate and cause damage in tissues and organs)
  • Fabhalta (iptacopan) – new indication
    Treatment of complement 3 glomerulopathy (a kidney disease) and paroxysmal nocturnal haemoglobinuria, a disease in which there is an excessive breakdown of blood cells
  • Jaypirca (pirtobrutinib) – new indication
    Treatment of blood cancer

Other EMA news

  • In a joint statement, EMA and the Heads of Medicines Agencies (HMA) warn the public about the dangers of unregulated advanced therapy medicinal products (ATMPs) offered to patients in the European Union.

February 2025

New medicines recommended for approval

  • Dyrupeg (pegfilgrastim) – biosimilar
    Treatment to shorten the duration of neutropenia and help prevent febrile neutropenia after cytotoxic chemotherapy
  • Eltrombopag Accord (eltrombopag) – generic
    Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C

New information on approved medicines

  • Breyanzi (lisocabtagene maraleucel) – new indication
    Treatment of follicular lymphoma and large B-cell lymphoma (types of blood cancer)

Supply shortages

  • Eldisine (vindesine)
    Treatment of different types of blood cancers, such as acute lymphoblastic leukemia and chemotherapy-refractory lymphoma, as well as certain solid tumors

January 2025

New medicines recommended for approval

  • Rytelo (imetelstat sodium) – orphan
    Treatment of anemia (low levels of red blood cells)
  • Zefylti (filgrastim) – biosimilar
    Treatment of neutropenia (low level of white blood cells) in patients having chemotherapy or a bone marrow transplant

New information on approved medicines

  • Blincyto (blinatumomab) – extension of indication
    Treatment of B-precursor acute lymphoblastic leukemia (a type of blood cancer)